Want to see FR:ALVIO full AI Analyst Report?
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.06 - €0.98
Previous CloseN/A
Volume8.86K
Average Volume (3M)877.23K
Market Cap
€312.32M
Enterprise Value€77.01M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta-0.50
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding567,668,640
10 Day Avg. Volume408,929
30 Day Avg. Volume877,229
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe 2025 revenue rebound indicates stronger operating traction in the development business. If maintained, this combination can provide more resources for oncology R&D, improve the economics of advancing candidates, and support business momentum over the next several quarters.
Improved Cash GenerationTurning operating and free cash flow positive after several years of burn is a meaningful improvement in internal funding capacity. Although consistency is not established, sustained cash generation could reduce immediate reliance on outside capital and support ongoing development activities.
Strong Gross MarginsGross margins of roughly 67–71% provide a favorable base for a clinical-stage biotech’s development activities, indicating that reported revenue retains meaningful value after direct costs. Maintaining this profile would support reinvestment as oncology programs progress despite current losses.
Bears Say
Elevated LeverageThe elevated debt-to-equity ratio and large swings in equity leave the company with limited financial flexibility. High leverage can constrain investment in oncology programs, increase pressure on future financing decisions, and make the balance sheet less resilient if operating results weaken.
Persistent Net LossesDespite improved revenue and margins, the company remains materially loss-making, showing that its current operations do not yet provide consistent earnings power. Continued net losses can consume financial resources and increase dependence on cash generation or external funding to sustain development.
External Funding DependenceThe company’s clinical-stage model relies mainly on capital raises and potential partnering payments because product sales are not meaningful before regulatory approval. This creates ongoing funding dependence and leaves development capacity tied to financing and successful advancement of candidates.
Valerio Therapeutics News
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.06 and its highest was €0.98 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €312.32M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 567,668,640 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―